The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 365.00
Bid: 360.00
Ask: 370.00
Change: -2.00 (-0.54%)
Spread: 10.00 (2.778%)
Open: 365.00
High: 365.00
Low: 365.00
Prev. Close: 367.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holdings in Company

6 Oct 2021 07:00

RNS Number : 1277O
MaxCyte, Inc.
06 October 2021
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

US57777K1060

Issuer Name

MAXCYTE, INC.

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Vitruvian Partners LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

Life Tech S.à r.l.

Luxembourg

Luxembourg

5. Date on which the threshold was crossed or reached

24-Sep-2021

6. Date on which Issuer notified

28-Sep-2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

3.110000

0.000000

3.110000

3122500

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

US57777K1060

3122500

3.110000

Sub Total 8.A

3122500

3.110000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

- The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP and isd eemed to be the ultimate beneficial owner of Life Tech S.à r.l.- The voting rights attached to shares disclosed herein - 3,122,500, equivalent to 3.11% of issuer's voting rights - are comprised by 2,222,500 LSE (AIM) listed shares (LSE SEDOL: BYVJZ42) and by 900,000 US NASDAQ listed shares (NASDAQ: SEDOL BKMQF66).

12. Date of Completion

28-Sep-2021

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDKPBBKBDBFKK
Date   Source Headline
24th Jan 20227:30 amRNSPreliminary Unaudited Q4 & FY 2021 Revenue Results
29th Dec 20213:30 pmRNSHoldings in Company
1st Dec 20215:00 pmRNSTotal Voting Rights
23rd Nov 20217:32 amRNSPurchase of Common Stock
17th Nov 20215:36 pmRNSExercise of options and PDMR Dealing
11th Nov 20217:00 amRNSMaxCyte Reports Third Quarter Financial Results
3rd Nov 20211:00 pmRNSAppointment of Chairman of the Board
29th Oct 20215:01 pmRNSResult of AGM
28th Oct 20213:00 pmRNSLicense with Nkarta, Inc.
26th Oct 20217:00 amRNSNotice of Results
6th Oct 20217:00 amRNSHoldings in Company
1st Oct 20213:49 pmRNSNotice of AGM and Change of Director
1st Oct 202112:36 pmRNSTotal Voting Rights
17th Sep 20212:35 pmRNSMaxCyte Set to Join Russell 2000® Index
14th Sep 20217:00 amRNSHalf-year Report
14th Sep 20217:00 amRNSFiling of Form 10-Q
2nd Sep 20212:26 pmRNSNotice of Results
10th Aug 20217:00 amRNSGrant of Options
9th Aug 20217:00 amRNSLicense with Sana Biotechnology
5th Aug 20214:05 pmRNSAmendments to Bylaws
3rd Aug 20213:51 pmRNSClosing of Offering
2nd Aug 20217:00 amRNSFull Exercise of Over-Allotment Option
30th Jul 20214:43 pmRNSSecond Price Monitoring Extn
30th Jul 20214:36 pmRNSPrice Monitoring Extension
30th Jul 20217:00 amRNSPricing of Offering and Approval to List on Nasdaq
26th Jul 202111:14 amRNSLaunch of Offering and Application to List
19th Jul 202112:30 pmRNSTermination of DI facility and transition to CDI
12th Jul 20217:00 amRNSS-1 Financial information & Directorate Change
12th Jul 20217:00 amRNSPublic Filing of Registration Statement with SEC
6th Jul 20215:36 pmRNSResult of Special Meeting
16th Jun 20217:01 amRNSPublication of Annual Report and Accounts
16th Jun 20217:00 amRNSStockholder Circular and Notice of Special Meeting
15th Jun 20217:00 amRNSMaxcyte Appoints Two New Non-Executive Directors
2nd Jun 20219:18 amRNSTotal Voting Rights
25th May 20217:00 amRNSSigning of Strategic Platform Licence
14th May 20217:00 amRNSProposed Dual-Listing on Nasdaq
13th May 20217:00 amRNSConsolidation of Trading Lines
20th Apr 20217:00 amRNSFull Year Results
15th Apr 20217:00 amRNSNotice of Full Year Results
1st Apr 20217:00 amRNSTotal Voting Rights
11th Mar 20213:01 pmRNSHolding(s) in Company
3rd Mar 20217:00 amRNSTotal Voting Rights
23rd Feb 20217:00 amRNSParticipation in Upcoming Investor Conferences
19th Feb 20217:00 amRNSDirector Dealings and Issue of Equity
17th Feb 20215:44 pmRNSGrant of Options
15th Feb 20214:32 pmRNSHolding(s) in Company
12th Feb 20211:59 pmRNSHolding(s) in Company
8th Feb 20212:59 pmRNSHolding(s) in Company
5th Feb 20219:01 amRNSPrice Monitoring Extension
4th Feb 20217:00 amRNSDirector Dealings and Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.